Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden

Peter Nordström, Marcel Ballin, Anna Nordström

Summary

Background Real-world evidence supporting vaccination against COVID-19 in individuals who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to investigate the long-term protection from a previous infection (natural immunity) and whether natural immunity plus vaccination (hybrid immunity) was associated with additional protection.

Methods In this retrospective cohort study, we formed three cohorts using Swedish nationwide registers managed by the Public Health Agency of Sweden, the National Board of Health and Welfare, and Statistics Sweden. Cohort 1 included unvaccinated individuals with natural immunity matched pairwise on birth year and sex to unvaccinated individuals without natural immunity at baseline. Cohort 2 and cohort 3 included individuals vaccinated with one dose (one-dose hybrid immunity) or two doses (two-dose hybrid immunity) of a COVID-19 vaccine, respectively, after a previous infection, matched pairwise on birth year and sex to individuals with natural immunity at baseline. Outcomes of this study were documented SARS-CoV-2 infection from March 20, 2020, until Oct 4, 2021, and inpatient hospitalisation with COVID-19 as main diagnosis from March 30, 2020, until Sept 5, 2021.

Findings Cohort 1 was comprised of 2 039 106 individuals, cohort 2 of 962 318 individuals, and cohort 3 of 567 810 individuals. During a mean follow-up of 164 days (SD 100), 34 090 individuals with natural immunity in cohort 1 were registered as having had a SARS-CoV-2 reinfection compared with 99 168 infections in non-immune individuals; the numbers of hospitalisations were 3195 and 1976, respectively. After the first 3 months, natural immunity was associated with a 95% lower risk of SARS-CoV-2 infection (adjusted hazard ratio [aHR] 0·05 [95% CI 0·05–0·05] p<0·001) and an 87% (0·13 [0·11–0·16]; p<0·001) lower risk of COVID-19 hospitalisation for up to 20 months of follow-up. During a mean follow-up of 52 days (SD 38) in cohort 2, 639 individuals with one-dose hybrid immunity were registered with a SARS-CoV-2 reinfection, compared with 1662 individuals with natural immunity (numbers of hospitalisations were eight and 113, respectively). One-dose hybrid immunity was associated with a 58% lower risk of SARS-CoV-2 reinfection (aHR 0·42 [95% CI 0·38–0·47]; p<0·001) than natural immunity up to the first 2 months, with evidence of attenuation thereafter up to 9 months (p<0·001) of follow-up. During a mean follow-up of 66 days (SD 53) in cohort 3, 438 individuals with two-dose hybrid immunity were registered immediately following a SARS-CoV-2 reinfection, compared with 808 individuals with natural immunity (numbers of hospitalisations were six and 40, respectively). Two-dose hybrid immunity was associated with a 66% lower risk of SARS-CoV-2 reinfection (aHR 0·34 [95% CI 0·31–0·39]; p<0·001) than natural immunity, with no significant attenuation up to 9 months (p=0·07). To prevent one reinfection in the natural immunity cohort during follow-up, 767 individuals needed to be vaccinated with two doses. Both one-dose (HR adjusted for age and baseline date 0·06 [95% CI 0·03–0·12]; p<0·001) and two-dose (HR adjusted for age and baseline date 0·10 [0·04–0·22]; p<0·001) hybrid immunity were associated with a lower risk of COVID-19 hospitalisation than natural immunity.

Interpretation The risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals who have survived and recovered from a previous infection remained low for up to 20 months. Vaccination seemed to further decrease the risk of both outcomes for up to 9 months, although the differences in absolute numbers, especially in hospitalisations, were small. These findings suggest that if passports are used for societal restrictions, they should acknowledge either a previous infection or vaccination as proof of immunity, as opposed to vaccination only.

Funding None.

Copyright © 2022 Elsevier Ltd. All rights reserved.

Introduction Evidence from clinical trials and real-world observational studies conclusively shows that vaccines against COVID-19 induce an immunity that effectively reduces the risk of SARS-CoV-2 infection and severe COVID-19 disease including hospitalisation and death.5–11 Research also shows that individuals who have recovered from an infection can develop naturally acquired immunity,
Research in context

Evidence before this study
We did not do a formal literature search; however, we searched standard databases such as PubMed, and used search engines such as Google, to identify relevant literature until Jan 4, 2022, using the key words “natural immunity”, “hybrid immunity”, “immunity”, “infection”, “vaccination”, “SARS-CoV-2,” and “COVID-19.” A meta-analysis of 15 cohort studies published on Sept 15, 2021, showed that naturally acquired immunity following recovery from a SARS-CoV-2 infection was associated with an 87% reduced risk of reinfection for up to 1 year. Yet, most national health-care authorities and government institutions recommend that individuals who have recovered from a documented previous infection should also be vaccinated. One reason for this might be evidence suggesting enhanced immunogenicity from vaccination in people with natural immunity, resulting in what is known as hybrid immunity. However, the primary reason for vaccinating people with natural immunity is probably the scarcity of evidence of the long-term protection against reinfection beyond 1 year.

Added value of this study
This registry-based study based on the total population of Sweden showed that natural immunity was associated with a 95% lower risk of SARS-CoV-2 reinfection and an 87% lower risk of COVID-19 hospitalisation than no immunity, for up to 20 months. In head-to-head comparisons, hybrid immunity induced by either one or two doses of a COVID-19 vaccine was associated with an additional risk reduction of SARS-CoV-2 reinfection compared with natural immunity for up to 9 months, although with small absolute differences. Furthermore, one-dose hybrid immunity was associated with an additional 94% lower risk of COVID-19 hospitalisation, and two-dose hybrid immunity with an additional 90% lower risk of COVID-19 hospitalisation, than natural immunity, although the number of hospitalisations were few.

Implications of all the available evidence
The risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation is low in individuals with a previous infection. Vaccination after recovering from a previous infection might result in additional risk reduction against reinfection and hospitalisation for up to 9 months, but the differences in absolute risk appear small. In relation to determining proof of immunity, distinguishing between immune and non-immune individuals could be more appropriate than the frequently used terminology of vaccinated and unvaccinated.

Methods

Study design and cohort construction
This retrospective cohort study was based on registry data covering the total population of Sweden. Vaccination in Sweden began on Dec 27, 2020, with older, frail individuals and individuals with specific comorbidities initially prioritised for vaccination.22 For the specific time period and data underlying the present study, Sweden had three large pandemic waves: the first was from March to June, 2020; the second from October, 2020, to January, 2021; and the third from February to May, 2021. There was also a small wave that started in August, 2021.

Individuals considered for inclusion were all people who had received at least one dose of any vaccine up until May 26, 2021 (N=3 664 421), and all individuals with a documented SARS-CoV-2 infection up until May 24, 2021 (N=13 319 899). Data on individuals vaccinated against COVID-19, including the type of vaccine received, were collected from the Swedish Vaccination Register and data on documented SARS-CoV-2 infections were collected from the SmiNet register; both registers are managed by the Public Health Agency of Sweden.23,24 All health-care providers in Sweden are obliged to report to these registers according to Swedish law, with an expected 100% coverage. For each of these individuals, we randomly sampled one individual from the general population using the Statistics Sweden database. Individuals were matched (1:1) on birth year, sex, and age.25
municipality, resulting in a total cohort of 5,833,003 unique individuals (figure 1), from Sweden’s total population of about 10.5 million individuals in June, 2021. This cohort was updated with respect to data on documented infections and vaccinations up to Oct 4, 2021. From this cohort, three study cohorts were formed. Cohort 1 was formed to compare natural immunity (exposed) to no immunity (unexposed). Here, all individuals with natural immunity with no previous vaccination (N=1,028,640) were matched randomly pairwise on birth year and sex to an individual from the total cohort. The matched individual was required to be alive at baseline, uninfected and without previous infection, and unvaccinated, otherwise a new match was sought from the remaining total cohort. A total of 1,019,553 exposed individuals could be pairwise matched to unexposed individuals, resulting in a total cohort size of 2,039,106 individuals. Baseline date for both individuals within each pair was the date of the documented previous infection in the exposed individual. The second and third cohorts were formed to do head-to-head comparisons of one-dose and two-dose hybrid immunity (exposed) versus natural immunity (unexposed). All individuals with one-dose hybrid immunity (N=763,213) or two-dose hybrid immunity (N=712,806) were randomly matched pairwise to an individual from the total cohort with natural immunity (N=1,028,640). Using the same principles for matching as in the first cohort, 481,159 matched pairs were identified in the second cohort (N=962,318), and 283,905 matched pairs were identified in the third cohort (N=567,810). Baseline date for both individuals within each pair in the second and third cohorts was the date of

| Derivation of analytical population | Matching | Cohort inclusion | Follow-up |
|------------------------------------|----------|-----------------|-----------|
| 1,331,989 individuals with a documented SARS-CoV-2 infection in SmiNet register up to May 24, 2021; 3,640,421 individuals identified from the Swedish Vaccination Register as having received at least one dose of a COVID-19 vaccine up to May 26, 2021 | Matching | 5,833,003 unique individuals after matching; this cohort was updated with data on documented infections and vaccinations up to Oct 4, 2021 | Each exposed individual was randomly matched pairwise to one unexposed individual from the total cohort (N=5,833,003) based on birth year and sex |
| 1,028,640 individuals (exposed) with a documented infection up to Oct 3, 2021, who were unvaccinated at the date of infection, were identified (cohort 1) | Matching | 763,213 individuals (exposed) with a documented infection followed by one dose of vaccine up Oct 3, 2021, were identified (cohort 2) | In cohort 1, matched individuals were excluded if they had died, or if they had a documented infection or a first dose of vaccine at the date of documented infection in the exposed individual or earlier, and a new individual was searched from the rest of the total cohort |
| 712,806 individuals (exposed) with a documented infection followed by two doses of vaccine up to Oct 3, 2021, were identified (cohort 3) | Matching | | In cohorts 2 and 3, matched individuals were excluded if they had died or if they had a first dose of vaccine at the date of the first dose of vaccine in the exposed individual or earlier, and a new individual was searched from the rest of the total cohort |
| Cohort 1: Natural immunity vs no immunity | 1,019,553 matched pairs could be identified (N=2,039,106), in each pair, baseline date of both individuals was the date of the documented infection in the exposed individual | Cohort 2: One-dose hybrid immunity vs natural immunity | Mean 164 (SD 100) |
| Cohort 2: One-dose hybrid immunity vs natural immunity | 481,159 matched pairs could be identified (N=962,318), in each pair, baseline date of both individuals was the date of the first dose of vaccine in the exposed individual | Cohort 3: Two-dose hybrid immunity vs natural immunity | Mean 52 days (SD 38) |
| Cohort 3: Two-dose hybrid immunity vs natural immunity | 283,905 matched pairs could be identified (N=567,810), in each pair, baseline date of both individuals was the date of the second dose of vaccine in the exposed individual | Cohort 1: Natural immunity vs no immunity | Mean 66 days (SD 53) |

**Figure 1:** Selection of the cohort
first dose of vaccine and second dose of vaccine in the exposed individual, respectively. The present study was approved by the Swedish Ethical Review Authority (495/2021), who waived the requirement of obtaining informed consent given the retrospective study design.

Study definitions
No immunity was defined as being unvaccinated and not having a documented previous SARS-CoV-2 infection at baseline. Natural immunity was defined as having a documented previous infection but being unvaccinated at baseline. One-dose hybrid immunity was defined as having a documented previous infection and having received a single dose of either ChAdOx1 nCoV-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) either before or after infection at baseline. Two-dose hybrid immunity was defined as having a documented previous infection and having received two doses of any of the vaccines at baseline, with at least the second dose given after the infection.

Outcomes
This study had two outcomes. The first outcome was SARS-CoV-2 infection as documented in the SmiNet register from March 30, 2020, until Oct 4, 2021. Given that all confirmed infections are documented in this register, this outcome was defined as a SARS-CoV-2 infection of any severity for the present study. The second outcome was inpatient hospitalisation with COVID-19 as the main diagnosis and reason for admission, traced using the National Inpatient Register and the International Classification of Disease (ICD) version 10 code U071. This register is managed by the National Board of Health and Welfare. Hospitalisations in the cohorts could be tracked from March 30, 2020, until Sept 5, 2021. Only hospitalisations and infections that occurred more than 14 days after baseline were evaluated. Planned follow-up for assessment of outcomes was 20 months for cohort 1 and was 9 months for cohorts 2 and 3, and follow-up time in days was counted until the date of either a confirmed SARS-CoV-2 infection or COVID-19 hospitalisation, a vaccination after baseline (for unvaccinated individuals and individuals with one-dose hybrid immunity), death, or end of possible follow-up time (Oct 4, 2021, for the infection outcome and Sept 5, 2021, for the hospitalisation outcome), whichever occurred first.

Statistical analysis
Hazards over time for the outcome of SARS-CoV-2 infection based on immunity status were illustrated using proportional hazards models with 95% CIs and restricted cubic splines. The knots were placed in default position. To compare the risk of both outcomes (SARS-CoV-2 infection and COVID-19 hospitalisation) on the basis of immunity status, Cox regression was used to calculate hazard ratios (HR). To adjust for the matched samples, 95% CIs were estimated using robust standard errors by the variance–covariance matrix (VCE) command and robust option in Stata. To formally test whether the associations were time dependent, Schoenfeld’s residuals were evaluated using estat phtest command in Stata. Because the test indicated that the proportional hazard assumption was violated (p<0·05) for some of the main exposures, the associations were also evaluated in time intervals in the cohorts. In all cohorts, the first model was adjusted for age and baseline date, to account for variations in infection pressure during follow-up (reported as HR). The second model included the additional covariates sex, homemaker service (yes or no), education (six categories), marital status (five categories), whether the individual was born in Sweden or not, and nine diagnoses at baseline (yes or no; reported as adjusted [a]HR). To investigate whether there was effect measure modification of the associations between the exposure and outcome by any of the covariates, interaction analyses were done using product terms created by multiplying the variable coding for immunity status at baseline by each respective covariate, which were added to the fully adjusted Cox model. Given that the interaction terms were significant (p<0·001) for many covariates, associations were investigated in subgroups according to these covariates, including type of vaccine for two-dose hybrid immunity compared with natural immunity. Other subgroup analyses were by age, sex, comorbidity status (compared with natural immunity) and by other covariates, including type of vaccine for two-dose hybrid immunity compared with natural immunity. Other subgroup analyses were by age, sex, marital status, level of highest education, and sex for all individuals in the cohort was obtained from Statistics Sweden. Definitions of comorbidities are provided in appendix p 2.

All analyses were done using SPSS version 27.0 for Mac and Stata version 16·1 for Mac. A two-sided p-value of less than 0·05 or a HR with a 95% CI not crossing 1 was considered significant. In the two-dose hybrid immunity versus natural immunity cohort, the number needed to vaccinate to prevent one reinfection in individuals with natural immunity was estimated as the difference in event rate between the two groups, inverted.
Role of the funding source
There was no funding source for this study.

Results
According to the SmiNet register, 94·4% of infections were confirmed using PCR, 4·8% through sequencing, and the remaining through a combination of methods. In cohort 1 (natural immunity vs no immunity), the mean baseline date was Jan 1, 2021, and the median age was 39·2 years (IQR 25·5–53·0; table 1). Individuals in cohort 2 (one-dose hybrid immunity vs natural immunity) had a median age of 39·9 years (28·3–52·4) at baseline and the baseline date was June 7, 2021, more than 6 months later than the baseline date in cohort 1, with a lower resulting infection pressure during follow-up, since individuals in cohort 2 and 3 missed the first wave, and shorter follow-up time. Individuals in cohort 3 (two-dose hybrid immunity vs natural immunity) had a median age of 37·6 years (27·8–50·3) with a baseline date of July 9, 2021. Individuals with natural immunity in the second and third cohorts were more often born outside of Sweden than those with natural immunity in the first cohort. Participant characteristics at different time intervals during follow-up in the cohorts are in the appendix (pp 3–4).

The number of confirmed SARS-CoV-2 infections in Sweden during follow-up, and SARS-CoV-2 variants sequenced in Sweden during the study period, are shown

| Cohort 1* | Cohort 2† | Cohort 3‡ |
|-----------|-----------|-----------|
| **Age, years** | | | |
| Natural immunity (n=1019 (553) | 39·2 (25·5–53·0) | 39·9 (28·3–52·4) | 37·6 (27·8–50·3) |
| No immunity (n=1019 (553)) | 39·2 (25·5–53·0) | 39·9 (28·3–52·4) | 37·6 (27·8–50·3) |
| **Sex** | | | |
| Female | 518 (50·9%) | 249 (51·8%) | 155 (54·8%) |
| Male | 501 (49·1%) | 236 (48·2%) | 128 (45·2%) |
| **Homemaker service recipient§** | | | |
| No | 982 (93·5%) | 918 (1·9%) | 788 (2·1%) |
| Yes | 37 (3·4%) | 23 (0·5%) | 20 (0·6%) |
| **Born in Sweden** | | | |
| No | 291 (28·9%) | 147 (2·9%) | 78 (2·1%) |
| Yes | 728 (71·1%) | 287 (5·7%) | 307 (9·9%) |
| **Marital status** | | | |
| Married | 366 (35·9%) | 184 (39·4%) | 101 (34·5%) |
| Not married | 526 (51·6%) | 245 (51·1%) | 153 (51·2%) |
| Divorced | 92 (9·0%) | 39 (8·0%) | 22 (7·3%) |
| Widow or widower | 24 (2·4%) | 7 (1·4%) | 5 (1·6%) |
| Other | 13 (1·3%) | 17 (3·4%) | 12 (4·0%) |
| **Education** | | | |
| Elementary school for <9 years | 40 (3·9%) | 14 (0·3%) | 8 (0·3%) |
| Elementary school for 9 years | 110 (10·9%) | 55 (11·6%) | 31 (10·4%) |
| Secondary school for 2 years | 15 (1·5%) | 68 (14·2%) | 37 (12·0%) |
| Secondary school for >2 years | 45 (4·4%) | 26 (5·7%) | 18 (6·0%) |
| University | 35 (3·4%) | 192 (40·0%) | 114 (39·5%) |
| Unknown | 116 (11·4%) | 25 (5·3%) | 14 (4·5%) |
| **Comorbidities** | | | |
| Myocardial infarction | 11 (1·1%) | 10 (1·0%) | 7 (1·0%) |
| Stroke | 117 (1·2%) | 23 (0·9%) | 15 (0·5%) |
| Diabetes | 46 (4·5%) | 25 (5·3%) | 15 (0·5%) |
| Hypertension | 141 (13·6%) | 68 (14·2%) | 37 (12·0%) |
| Kidney failure | 96 (0·9%) | 45 (0·9%) | 25 (0·8%) |
| COPD | 805 (7·9%) | 309 (6·6%) | 179 (5·7%) |
| Asthma | 67 (0·6%) | 31 (0·6%) | 19 (0·6%) |
| Depression | 150 (1·7%) | 75 (1·5%) | 49 (1·5%) |
| Cancer | 24 (0·2%) | 10 (0·2%) | 6 (0·2%) |

Data are n (%) or median (IQR). COPD=chronic obstructive pulmonary disease. *Mean baseline date was Jan 1, 2021 (range Jan 25, 2020, to Oct 3, 2021). †Mean baseline date was June 7, 2021 (Dec 27, 2020, to Sept 27, 2021). ‡Mean baseline date was July 9, 2021 (Dec 30, 2020, to Oct 3, 2021). §Homemaker services include domestic services provided to individuals (primarily older individuals) who live at home but need help with shopping, cleaning, meal preparation, and similar tasks.

Table 1: Baseline characteristics of the three study cohorts
During the study period there were three large waves of COVID-19. The first two waves (in March–June, 2020, and October, 2020, to January, 2021) occurred before the sequencing data were available, and before the alpha variant became dominant in Sweden. Based on the sequencing data, the alpha variant dominated during the third wave (in February–May, 2021) and the delta variant dominated from July, 2021, onwards (thus including the fourth wave that started in August, 2021).

During a mean follow-up of 164 days (SD 100), 34090 individuals with natural immunity were registered as having had a SARS-CoV-2 reinfection compared with 99168 infections in non-immune individuals. Compared with no immunity, natural immunity was associated with a gradually reduced risk of reinfection during the first 3 months of follow-up (figure 2A). After 3 months, the associated risk reduction was 95% (aHR 0.05 [95% CI 0.05–0.05]; p<0.001), with no signs of attenuation for up to 20 months of follow-up (figure 2A; table 2). The associations appeared to attenuate with increasing age (table 2), in people born outside Sweden (data not shown), with increasing education level (data not shown), and in people receiving a homemaker service (table 2; p<0.001 for all).

For the outcome of COVID-19 hospitalisation (table 3), 3195 people with natural immunity were hospitalised and 1976 people with no natural immunity were hospitalised; natural immunity was associated with increased risk during the first 3 months of follow-up, but from 3 months onwards there was an associated 87% lower risk of COVID-19 hospitalisation in people with natural immunity than in people with no immunity (aHR 0.13, 95% CI 0.11–0.15; p<0.001) for up to 19 months of follow-up. The associations were weaker with increasing age and in individuals receiving a homemaker service (both p<0.001).

During a mean follow-up of 52 days (SD 38), 639 individuals with one-dose hybrid immunity were registered with a SARS-CoV-2 reinfection, compared with 1662 individuals with natural immunity (appendix p 6). The associations attenuated with increasing follow-up time (figure 2B, p<0.001). Thus, during the first 2 months of follow-up, compared with natural immunity, one-dose hybrid immunity was associated with a 58% lower risk of reinfection (aHR 0.42 [95% CI 0.38–0.47]; p<0.001), which was reduced to 45% (0.55 [0.39–0.76]; p<0.001) from 2 months onwards. Overall, the associations were weaker in older individuals, and individuals with comorbidities (p<0.001; appendix p 6). With respect to COVID-19 hospitalisations, eight individuals were hospitalised among individuals with one-dose hybrid immunity (incidence rate [IR] 0.04) compared with 113 individuals with natural immunity (IR 0.56; HR 0.06 [95% CI 0.03–0.12]; p<0.001).

During a mean follow-up of 66 days (SD 53), 438 individuals with two-dose hybrid immunity were registered as having had a SARS-CoV-2 reinfection, compared with 808 individuals with natural immunity (appendix p 7). Correspondingly, the number of individuals with natural immunity needed to be double vaccinated to prevent one reinfection during follow-up was 767. Overall, two-dose hybrid immunity was
associated with a 66% lower risk of reinfection than natural immunity (aHR 0·34 [95% CI 0·31–0·39]; p<0·001). During the first 2 months of follow-up, two-dose hybrid immunity was associated with a 69% (0·31 [0·26–0·36]; p<0·001) lower risk of reinfection than natural immunity. From 2 months onwards, the associated risk reduction was 56% (0·44 [0·35–0·56]; p<0·001), with no significant attenuation up to 9 months (p=0·07; figure 2C). Overall, the associations were 56% (0·44 [0·35–0·56]; p<0·001) lower risk of reinfection with two-dose hybrid immunity compared with mRNA vaccines (aHR 0·32 [95% CI 0·25–0·40]; p<0·001). We also found a significant association with comorbidities (p<0·001; appendix p 7). With respect to vaccine types, a significant association was observed for mRNA vaccines (aHR 0·32 [95% CI 0·26–0·37]; p<0·001) but not ChAdOx1 nCoV-19 (0·75 [0·41–1·37]; p=0·35; appendix p 7).

With respect to COVID-19 hospitalisations, six individuals with two-dose hybrid immunity were hospitalised (IR 0·04) compared with 40 individuals with natural immunity (IR 0·44; HR 0·10 [95% CI 0·04–0·22]; p<0·001).

**Discussion**

In this nationwide study, immunity acquired from a previous infection was associated with a low risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation for up to 20 months. In head-to-head comparisons, immunity acquired from a previous infection plus either one or two doses of a COVID-19 vaccine was associated with a greater reduced risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation for up to 9 months than previous infection only, although with small differences in absolute numbers during follow-up.

Many authorities recommend that all individuals should receive both primary series vaccination and booster vaccination irrespective of whether they have previously been infected. The strongest argument behind this recommendation might be the scarcity of evidence on long-term protection from natural immunity. A meta-analysis of 15 observational studies showed that natural immunity was associated with an 87% lower risk of reinfection than non-immunity for up to 1 year.13 Our study extends the body of evidence with up to 20 months after baseline until a maximum follow-up of 613 days (mean 164 days [SD 100]). IR=incidence rate. *Adjusted for age, baseline date, sex, marital status, homemaker service, place of birth, education, and comorbidities according to table 1. †Comparison is with the total population.

| Follow-up time in total cohort | Natural immunity (n=1 039 553) | No immunity (n=1 039 553) | Hazard ratio (95% CI) |
|---|---|---|---|
| Number of events | IR per 100 000 person-days | Number of events | IR per 100 000 person-days | Adjusted for age and baseline date | Fully adjusted* |
| 14 days to 3 months (n=2 039 106) | 31 272 | 17·9 | 54 368 | 34·2 | 0·54 (0·53–0·55) | 0·52 (0·52–0·53) |
| 3–6 months (n=1 477 887) | 18 144 | 1·4 | 33 014 | 29·3 | 0·55 (0·54–0·55) | 0·55 (0·54–0·55) |
| 6–9 months (n=783 767) | 700 | 0·7 | 7 588 | 8·9 | 0·08 (0·08–0·09) | 0·08 (0·07–0·09) |
| ≥3 months (n=3 033 236) | 304 | 0·6 | 4 198 | 8·5 | 0·07 (0·06–0·08) | 0·07 (0·06–0·08) |
| ≥3 months (n=1 477 887) | 2818 | 1·7 | 44 800 | 31·2 | 0·06 (0·05–0·06) | 0·05 (0·05–0·05) |

### Events after ≥3 months follow-up, by sex

| | Male (n=7 226 657) | Female (n=7 553 290) |
|---|---|---|
| Number of events | IR per 100 000 person-days | Number of events | IR per 100 000 person-days | Adjusted for age and baseline date | Fully adjusted* |
| Events after ≥3 months follow-up, by sex | | |
| Male (n=7 226 657) | 1151 | 1·4 | 22 790 | 32·9 | 0·05 (0·04–0·05) | 0·04 (0·04–0·04) |
| Female (n=7 553 290) | 1667 | 2·0 | 22 010 | 29·6 | 0·07 (0·06–0·07) | 0·06 (0·06–0·07) |

### Events after ≥3 months follow-up, by age

| | <50 years (n=1 102 189) | 50–64 years (n=2 743 315) | 65–79 years (n=7 490) | ≥80 years (n=27 305) | Events after ≥3 months follow-up in those receiving homemaker service (N=19 324)† | Events after ≥3 months follow-up in those with any comorbidity (n=44 752)† |
|---|---|---|---|---|---|---|
| Number of events | IR per 100 000 person-days | Number of events | IR per 100 000 person-days | Adjusted for age and baseline date | Fully adjusted* |
| <50 years (n=1 102 189) | 2070 | 1·6 | 37 775 | 35·3 | 0·05 (0·05–0·06) | 0·04 (0·04–0·05) |
| 50–64 years (n=2 743 315) | 547 | 2·0 | 6 139 | 23·4 | 0·08 (0·08–0·09) | 0·08 (0·07–0·09) |
| 65–79 years (n=7 490) | 103 | 1·5 | 563 | 7·8 | 0·20 (0·16–0·25) | 0·18 (0·15–0·23) |
| ≥80 years (n=27 305) | 98 | 4·3 | 323 | 8·4 | 0·55 (0·44–0·70) | 0·42 (0·33–0·53) |

### Events after ≥3 months follow-up in those receiving homemaker service (N=19 324)†

| | Number of events | IR per 100 000 person-days | Adjusted for age and baseline date | Fully adjusted* |
|---|---|---|---|---|
| Events after ≥3 months follow-up in those receiving homemaker service (N=19 324)† | 104 | 4·3 | 258 | 12·9 | 0·33 (0·26–0·41) | 0·32 (0·25–0·40) |

### Events after ≥3 months follow-up in those with any comorbidity (n=44 752)†

| | Number of events | IR per 100 000 person-days | Adjusted for age and baseline date | Fully adjusted* |
|---|---|---|---|---|
| Events after ≥3 months follow-up in those with any comorbidity (n=44 752)† | 974 | 2·1 | 11 551 | 26·9 | 0·08 (0·07–0·08) | 0·07 (0·07–0·08) |

In each matched pair, the baseline date for both individuals was set as the date of the first documented previous infection in the individual with natural immunity. Outcome events were traced from 14 days after baseline until a maximum follow-up of 613 days (mean 164 days [SD 100]). IR=incidence rate. *Adjusted for age, baseline date, sex, marital status, homemaker service, place of birth, education, and comorbidities according to table 1. †Comparison is with the total population.
Articles

| Follow-up time in total cohort | Natural immunity (n=1018 536) | No immunity (n=1 018 636) | Hazard ratio (95% CI) |
|-------------------------------|------------------------------|--------------------------|----------------------|
|                               | Number of events | IR per 100 000 person-days | Number of events | IR per 100 000 person-days | Adjusted for age and baseline date | Fully adjusted† |
| 14 days to 3 months (n=2 037 272) | 3065 | 3.6 | 1030 | 1.3 | 3.21 (2.98–3.45) | 3.02 (2.80–3.26) |
| 3–6 months (n=1 546 582) | 77 | 0.6 | 632 | 0.53 | 0.12 (0.09–0.15) | 0.11 (0.09–0.14) |
| 6–9 months (n=773 806) | 28 | 0.03 | 190 | 0.21 | 0.18 (0.12–0.26) | 0.15 (0.10–0.22) |
| >9 months (N=2 601 984) | 25 | 0.06 | 124 | 0.27 | 0.28 (0.18–0.42) | 0.22 (0.15–0.34) |
| ≥3 months (n=1 546 582) | 130 | 0.08 | 946 | 0.63 | 0.14 (0.12–0.17) | 0.13 (0.11–0.16) |

Events after ≥3 months follow-up, by sex

| Male (n=750 942) | 80 | 0.10 | 548 | 0.75 | 0.15 (0.12–0.19) | 0.14 (0.11–0.17) |
| Female (n=789 640) | 50 | 0.06 | 398 | 0.51 | 0.13 (0.10–0.18) | 0.12 (0.09–0.16) |

Events after ≥3 months follow-up, by age

| <50 years (N=1 160 812) | 27 | 0.02 | 420 | 0.37 | 0.06 (0.04–0.09) | 0.06 (0.04–0.09) |
| 50–64 years (n=2 835 569) | 46 | 0.17 | 338 | 1.3 | 0.13 (0.10–0.18) | 0.12 (0.09–0.17) |
| 65–79 years (n=74 643) | 43 | 0.65 | 92 | 1.3 | 0.50 (0.35–0.71) | 0.43 (0.29–0.63) |
| ≥80 years (n=27 558) | 14 | 0.62 | 96 | 2.5 | 0.25 (0.14–0.45) | 0.17 (0.10–0.31) |

Events after ≥3 months follow-up in those receiving homemaker service (n=19 626)†

| 27 | 1.0 | 77 | 3.5 | 0.26 (0.16–0.43) | 0.22 (0.13–0.36) |

Events after ≥3 months follow-up in those with any comorbidity (n=459 097)†

| 87 | 0.19 | 615 | 1.2 | 0.18 (0.17–0.93) | 0.16 (0.13–0.20) |

In each matched pair, the baseline date for both individuals was set as the date of the first documented previous infection in the individual with natural immunity. Outcome events were traced from 14 days after baseline until a maximum follow-up of 588 days (mean 165 days [SD 95]). COPD=chronic obstructive pulmonary disease. *Adjusted for age, baseline date, sex, marital status, homemaker service, place of birth, education, and comorbidities according to table 1. †Comparison is with the total population.

Table 3: Risk of COVID-19 hospitalisation for individuals with natural immunity compared with individuals with no immunity

infection, but for those who survived, natural immunity was associated with 87% protection against COVID-19 hospitalisation during the rest of follow-up. The associated level of protection remained high (78%) even from 9 up to 19 months of follow-up, altogether indicating long-lasting protection, including against severe disease, from natural immunity. Together, these findings might suggest that any passports or documents used to identify whether a person is immune or not, and used for societal restrictions, should acknowledge either a previous infection or vaccination as proof of immunity, as opposed to vaccination only. This policy could have social and equity implications, especially for individuals in countries with low vaccine coverage, considering also that the dominant omicron variant is less sensitive to current vaccines than previous variants.27

The associated protection from natural immunity was lower in older individuals and in individuals receiving a homemaker service, as previously reported in a nationwide study from Denmark.28 Because these individuals have higher risk of critical illness and death from COVID-19,29,30 boosting their level of protection is important. Thus, as further shown through head-to-head comparisons, individuals who had recovered from a previous infection had an additional associated protection against SARS-CoV-2 reinfection if they had also been vaccinated, although the associations appeared slightly weaker in older individuals. The associated benefit seemed slightly stronger and more stable for those given two doses rather than one dose of vaccine, and it was more clearly detectable among those vaccinated with mRNA vaccines than ChAdOx1 nCoV-19 (in whom the association was weaker and not significant, although the number of participants contributing to this analysis was small). This finding is supported by a systematic review and meta-regression of vaccine effectiveness studies, which suggested faster waning of immunity with ChAdOx1 nCoV-19 than with BNT162b2.31 In the present study, there was also evidence of waning protection, especially for those with one-dose hybrid immunity. Waning protection from hybrid immunity was observed also in a recent Israeli preprint study of 5.7 million individuals.32 Additionally, the absolute risk reduction associated with hybrid immunity in the present study was small, indicating that to prevent one SARS-CoV-2 reinfection among those with natural immunity, 767 individuals would need to be vaccinated with two doses. Similar results were reported in an Israeli preprint study including 14 029 matched pairs,33 in which one additional dose of vaccine in those with natural immunity was associated with seven fewer cases of symptomatic reinfection, suggesting that about 2000 individuals needed to be vaccinated to prevent one reinfection. If these associations are causal, the overall
clinical relevance of these effects appears uncertain. In the present study, both one-dose and two-dose hybrid immunity were associated with protection against COVID-19 hospitalisation that was above the level of protection afforded by natural immunity. Because the primary aim of COVID-19 vaccination is to prevent severe disease, this finding is important. However, hospitalisations were rare, and because these analyses were based on a small number of cases, further studies should seek to assess the duration of protection of hybrid immunity against severe COVID-19.

This study has limitations that should be considered. First, the observational nature of the study limits the possibility to draw causal inferences, and there might be unknown confounding or bias not accounted for. For example, there is a risk of selection bias in individuals without a previous infection because they might be less inclined to take a PCR test than individuals with a documented previous infection, although this bias would not affect the estimates for the outcome of COVID-19 hospitalisation. Furthermore, as individuals with a previous infection were censored upon vaccination, the remaining cohort might have become less representative as time passed, introducing another selection bias. Although the associations were stable after adjustment for a rather rich set of covariates, the possibility of unmeasured confounding or bias remains. Moreover, in the analysis of hybrid immunity versus natural immunity, it is possible that vaccinated individuals with symptoms of infection are more prone to self-testing than individuals that remain unvaccinated after a documented infection. If so, this behaviour would attenuate the associations for the outcome of infection; however, it would not affect the associations with hospitalisation.

Second, mean baseline date was not the same in all cohorts, which could mean that variations in infection pressure and dominating SARS-CoV-2 variants during follow-up influenced the results, although we adjusted all models for baseline date. Third, we could not evaluate how different variants of SARS-CoV-2 influenced the associations, as we did not have access to such data on an individual level. Fourth, although individuals with a documented previous infection were excluded from the non-immune cohort, individuals with a previous asymptomatic infection might still have been included. Similarly, there is a risk of misclassification bias (ie, false-positive and false-negative tests, which could potentially result in underestimated associated benefits of natural immunity vs no immunity). However, the PCR test has been estimated to have a 97.1% sensitivity and 99.9% specificity.8 Fifth, it cannot be determined to what extent the results apply to the omicron variant. However, a study found that previous infection was associated with about 60% protection against symptomatic reinfection and about 90% protection against severe reinfection (hospitalisation or death) with the omicron variant.9

Strengths of the present study include the use of registers with 100% nationwide coverage and a follow-up time up of 20 months for the exposure of natural immunity and up to 9 months for hybrid immunity. Another strength is the head-to-head comparisons of hybrid immunity versus natural immunity, in which individuals in each pair were matched on birth year, had similar baseline characteristics, and started follow-up on the same date, and in which several covariates were adjusted for. Together, these methods reduce the risk of confounding when the aim is to perform direct comparisons. Finally, the large, population-based sample size increases the generalisability of the results to other countries with similar population structures.

Contributors
All authors conceived and designed the study. PN acquired the data and did the statistical analyses. PN and MB accessed and verified the underlying data and drafted the manuscript. PN and AN supervised the work. All authors interpreted the data, critically revised the manuscript for intellectual content, gave final approval of the version to be published, had full access to all the data, and had final responsibility for the decision to submit for publication.

Declaration of interests
We declare no competing interests.

Data sharing
The data files used for the present study are publicly unavailable according to regulations under Swedish law. However, access to all the data used for the present study can be requested from the National Board of Health and Welfare, Statistics Sweden, and the Public Health Agency of Sweden.

References
1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383: 2603–15.
2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–16.
3. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111.
4. Chenmaiteil H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 2021; 27: 1614–21.
5. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.6172 (delta) variant. N Engl J Med 2021; 385: 585–94.
6. Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime–boost vaccination against symptomatic COVID-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur 2021; 1: 100249.
7. Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: test negative design study. BMJ 2021; 374: n1943.
8. Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021; 385: 1761–73.
9. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021; 385: 1774–85.
10. Falsey AR, Sobieszczczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med 2021; 385: 2348–60.
11 Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397: 1819–29.

12 Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis 2021; 21: 1539–48.

13 Petrič M. Highly effective naturally acquired protection against COVID-19 persists for at least 1 year: a meta-analysis. J Am Med Dir Assoc 2021; 22: 2263–65.

14 Block J. Vaccinating people who have had COVID-19: why doesn’t natural immunity count in the US? BMJ 2021; 374: n2101.

15 US Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Feb 22, 2022. https://www.cdc.gov/vaccines/covid-19/interim-clinical-considerations/index.html (accessed Jan 3, 2022).

16 Wei J, Matthews PC, Steeber N, et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat Commun 2021; 12: 6250.

17 Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021; 374: abm0829.

18 Abu-Raddad LJ, Chemaitelly H, Ayoub H, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA 2021; 326: 1930–39.

19 Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid COVID-19 immunity. medRxiv 2021; published online Dec 5. https://doi.org/10.1101/2021.12.04.21267114 (preprint).

20 Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Engl J Med 2021; 385: 2385–86.

21 Kojima N, Klauser JD. Protective immunity after recovery from SARS-CoV-2 infection. Lancet Infect Dis 2022; 22: 12–14.

22 Public Health Agency of Sweden. Recommendations on order of priority of vaccination against COVID-19. https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-utbrott/covid-19/vaccination-mot-covid-19/rekommendationer-for-vaccination-mot-covid-19/ (accessed Mar 19, 2022).

23 Public Health Agency of Sweden. National Vaccination Register. https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/nationella-vaccinationsregistret/ (accessed June 16, 2021).

24 Public Health Agency of Sweden. SmiNet. https://www.folkhalsomyndigheten.se/smittskydd-beredskap/oversvakan och rapportering/sminet/ (accessed June 17, 2021).

25 Bergman J, Ballin M, Nordström A, Nordström P. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. Eur J Epidemiol 2023; 36: 287–98.

26 Nordström P, Ballin M, Nordström A. Risk of infection, hospitalization, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 2022; 399: 814–23.

27 UK Health Security Agency. COVID-19 vaccine surveillance report: week 4. Jan 27, 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf (accessed Jan 28, 2022).

28 Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet 2021; 397: 1204–12.

29 Ballin M, Bergman J, Kvipelto M, Nordström A, Nordström P. Excess mortality after COVID-19 in Swedish long-term care facilities. J Am Med Dir Assoc 2021; 22: 1574–80.e8.

30 Feikin D, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022; 399: 924–44.

31 Gazit S, Silezieinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv 2021; published online Aug 25. https://doi.org/10.1101/2021.08.24.21262415 (preprint).

32 Lorentzen HF, Schmidt SA, Sandholdt H, Benfield T. Estimation of the diagnostic accuracy of real-time reverse transcription quantitative polymerase chain reaction for SARS-CoV-2 using re-analysis of published data. Dan Med J 2020; 67: 67.

33 Altarawneh H, Chemaitelly H, Tang P, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N Engl J Med 2022; published online Feb 22. https://doi.org/10.1056/NEJMoa2200133.